Lin Pei
Department of Hematopathology, University of Texas-MD Anderson Cancer Center, Houston, TX 77070, USA.
Hematol Oncol Clin North Am. 2009 Aug;23(4):709-27. doi: 10.1016/j.hoc.2009.04.012.
Plasma cell myeloma is a heterogenous disease with variable clinical presentation and outcome. The prognosis is largely determined by tumor biology. Newer therapeutic agents are rapidly changing the survival outlook of myeloma patients.
浆细胞骨髓瘤是一种临床表现和预后各异的异质性疾病。预后很大程度上由肿瘤生物学特性决定。新型治疗药物正在迅速改变骨髓瘤患者的生存前景。